Get the Full Story, Without the Noise.

Published 2 days ago • loading... • Updated 2 days ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Summary by Missoulian

SAN FRANCISCO, July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $115 million of…

27 Articles

27 Articles

All

Left

3

Center

13

Right

1

Montana Standard

+26 Reposted by 26 other sources

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the closing of its underwritten public offering of $115 million of…

2 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources27

Leaning Left3Leaning Right1Center13Last Updated12 hours agoBias Distribution

76% Center

Bias Distribution

76% of the sources are Center

76% Center

+8

Untracked bias

+1

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Missoulian broke the news in Missoula, United States 2 days ago on Wednesday, July 2, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.